KZR

Kezar Life Sciences, Inc. (KZR) | Rumor.io

Kezar Life Sciences

KZR

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)92%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about KZR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Mar 30

Aurinia Pharmaceuticals has agreed to acquire Kezar Life Sciences for $6.955 in cash per share plus a Contingent Value Right (CVR).
The acquisition is related to Kezar's positive Phase 2 data for zetomipzomib, which bolsters Aurinia's pipeline.
The deal includes the right to certain proceeds relating to collaboration with Everest Medicines and Kezar's sale of its Sec61 program to Enodia.

Generated by AI

Sentiment

Of the messages about KZR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	78.2% +47.2
Bearish	—	—	—	21.8% -47.2

Bullish· Mar 30

Kezar Life Sciences ($KZR) has seen a notable strategic signal with Tang Capital, a 9% holder, committing to tender their shares and actively backing the transaction, indicating strong alignment with the deal and confidence in its future value.
The acquisition of Kezar Life Sciences by Aurinia Pharmaceuticals ($AUPH) for $6.955 per share plus a CVR has been confirmed, providing immediate liquidity for Kezar shareholders and setting a fundamental catalyst for the company's future.
$KZR has decisively breached the $6.67 resistance level, with high-volume surges confirming institutional accumulation and technical targets projecting a move toward $9.39, $9.42, or $9.45, depending on the source.

Bearish· Jun 29

$KZR's recent price action is a bad sign, as it broke higher Bollinger Band and may drop further.
The stock's complete volume fade after a huge run is a warning sign, especially since half of yesterday's gains were wiped out by close.
Bears are likely to win out in the short term, as the bulls are yet to take control of the stock, with the RSI indicator leaving the overbought zone.

Generated by AI

Topics

Of the messages about KZR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	3.44%
Announcements	—	—	—	80.28%
Controversies	—	—	—	0.92%
Earnings	—	—	—	0.46%
Macro	—	—	—	0%
Technical Analysis	—	—	—	14.91%

Analysts· Jul 16

Analysts at William Blair initiated coverage of Kezar Life Sciences $KZR with an Outperform rating.
Jefferies Financial Group Inc initiated coverage of Kezar Life Sciences $KZR with a Buy rating and a $23 price target.
Wells Fargo & Co initiated coverage of Kezar Life Sciences $KZR with an Outperform rating and a $30 price target.

Announcements· Mar 30

Aurinia Pharmaceuticals ($AUPH) to acquire Kezar Life Sciences ($KZR) in a cash + CVR deal, expanding its autoimmune pipeline with zetomipzomib (Phase 2).
The acquisition price is $6.955 per share in cash, plus a contingent value right (CVR) tied to zetomipzomib milestones, partnerships, asset sales, and excess cash.
The deal is expected to be completed within 20 days, with $KZR halted pending the news, and $AUPH's stock price impacted positively by the acquisition.

Technical Analysis· Mar 30

$KZR has shown choppy, indecisive price action, requiring increased volume to confirm its validity.
The stock has broken through a key resistance zone around $667.37, with significant volume (up to 805.03K) supporting this breakout.
The technical analysis suggests a potential target price of $944.63, with the acquisition by Enodia serving as a catalyst for this momentum.

Generated by AI

Community

Of the messages about KZR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	100%	57.32%
Newcomers	—	0%	0%	42.68%

Regulars· Mar 30

Aurinia Pharmaceuticals ($AUPH) has agreed to acquire Kezar Life Sciences ($KZR) for $6.955 in cash per share plus a Contingent Value Right (CVR), representing a premium of 12.18%.
The acquisition will provide immediate liquidity to Kezar shareholders, with the transaction expected to be completed within 20 days in Q2 2026.
The lead asset in the deal is zetomipzomib, a first-in-class drug in Phase 2 trials, which will be part of Aurinia's expanded autoimmune pipeline.

Newcomers· Mar 30

The acquisition of Kezar Life Sciences, Inc. by Aurinia Pharmaceuticals is being discussed, with the price per share in cash and the potential for a CVR being highlighted.
Newcomers are focusing on the positive Phase 2 data for zetomipzomib, which led to the acquisition and is expected to bolster Aurinia's pipeline.
Some users are speculating about potential future prices, with one user suggesting a price of $25 per share.

Generated by AI

Also Discussed

Investors talking about KZR also mention

#	Name	Attention
1	Pliant Therapeutics Inc.PLRX	0%0
2	ACHL - Achilles Therapeutics plc	——
3	SLRN - Acelyrin, Inc.	——
4	CWBR - CohBar, Inc.	——
5	CHN - The China Fund, Inc.	——
6	ALLK - Allakos Inc.	——
7	MKDWELL Tech Inc.MKDW	0%+0
8	ISEE - IVERIC bio, Inc.	——
9	Western Asset Inflation-Linked Income FundWIA	0%new
10	LanzaTech Global Inc. Common StockLNZA	0%new